Analyst Reco. Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.03 ^USD	+1.38%		+5.45%	-1.78%

Apr. 05	Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	MT
Apr. 04	Moderna Suffers Setback in Lawsuit by Arbutus	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Deutsche Bank Raises Roivant Sciences' Price Target to $15 From $14, Maintains Buy Rating	Apr. 03	MT
Goldman Sachs Raises Roivant Sciences' Price Target to $18 From $16, Maintains Buy Rating	Apr. 03	MT
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating	Apr. 03	MT
Wolfe Research Initiates Roivant Sciences With Outperform Rating, $17 Price Target	Feb. 15	MT
Deutsche Bank Initiates Coverage on Roivant Sciences With Buy Rating, $14 Price Target	Dec. 12	MT
Goldman Sachs Raises Roivant Sciences Price Target to $16 From $14, Maintains Buy Rating	23-09-27	MT
Wall St slides as rate concerns keep Treasury yields near 16-year peak	23-09-26	RE
Wall St poised for weak open as rate worries keep Treasury yields elevated	23-09-26	RE
HC Wainwright Adjusts Roivant Sciences Price Target to $18 From $15, Maintains Buy Rating	23-06-29	MT
Truist Securities Adjusts Price Target on Roivant Sciences to $23 From $19, Maintains Buy Rating	23-06-23	MT
BofA Securities Starts Roivant Sciences at Neutral With $10.50 Price Target	23-06-08	MT
JPMorgan Adjusts Roivant Sciences Price Target to $14 From $12, Maintains Overweight Rating	23-05-18	MT
HC Wainwright Adjusts Price Target on Roivant Sciences to $15 From $14, Maintains Buy Rating	23-05-17	MT
JPMorgan Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Overweight Rating	23-02-13	MT
Goldman Sachs Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Buy Rating	23-01-19	MT
Citigroup Adjusts Price Target on Roivant Sciences to $14 From $11, Maintains Buy Rating	23-01-05	MT
SVB Securities Adjusts Price Target on Roivant Sciences to $10 From $8, Maintains Outperform Rating	22-12-19	MT
Citigroup Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Buy Rating	22-11-15	MT
Citigroup Raises Roivant Sciences' Price Target to $10 From $9, Maintains Buy Rating	22-08-16	MT
SVB Securities Adjusts Roivant Sciences' Price Target to $7 from $6, Keeps Outperform Rating	22-06-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Analyst Reco.

Filters